Should I buy or sell Monte Rosa Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GLUE shares. View GLUE analyst ratings or view top-rated stocks .

What is Monte Rosa Therapeutics' stock price target for 2024?

3 brokers have issued 1-year price objectives for Monte Rosa Therapeutics' stock. Their GLUE share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 85.8% from the stock's current price. View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts .

How have GLUE shares performed in 2024?

Monte Rosa Therapeutics' stock was trading at $5.65 on January 1st, 2024. Since then, GLUE stock has increased by 4.8% and is now trading at $5.92. View the best growth stocks for 2024 here .

Are investors shorting Monte Rosa Therapeutics?

Monte Rosa Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 1,680,000 shares, a drop of 8.2% from the March 15th total of 1,830,000 shares. Based on an average daily volume of 150,300 shares, the short-interest ratio is currently 11.2 days. Approximately 5.3% of the company's shares are sold short. View Monte Rosa Therapeutics' Short Interest .

When is Monte Rosa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GLUE earnings forecast .

How were Monte Rosa Therapeutics' earnings last quarter?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its earnings results on Thursday, March, 14th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.01.

What ETF holds Monte Rosa Therapeutics' stock?

Range Cancer Therapeutics ETF holds 18,664 shares of GLUE stock, representing 1.26% of its portfolio.

When did Monte Rosa Therapeutics IPO?

Monte Rosa Therapeutics (GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.

How do I buy shares of Monte Rosa Therapeutics?

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GLUE

Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)

Free GLUE Stock Alerts

$5.92

+0.12 (+2.07%)

(As of 04:00 PM ET)

Compare

Today's Range: $5.69
▼
$6.08
50-Day Range: $4.26
▼
$8.46
52-Week Range: $2.44
▼
$8.84

Volume: 185,357 shs
Average Volume: 149,544 shs
Market Capitalization: $296.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get Monte Rosa Therapeutics alerts:

Monte Rosa Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 85.8% Upside
$11.00 Price Target
Short Interest: Bearish
5.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.24
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.25) to ($2.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.09 out of 5 stars

Medical Sector

548th out of 919 stocks

Biological Products, Except Diagnostic Industry

87th out of 152 stocks

3.3

Analyst's Opinion

Consensus Rating
Monte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Monte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.31% of the float of Monte Rosa Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Monte Rosa Therapeutics has recently decreased by 8.20%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Monte Rosa Therapeutics does not currently pay a dividend.
Dividend Growth
Monte Rosa Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLUE.

3.5

News and Social Media Coverage

News Sentiment
Monte Rosa Therapeutics has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Monte Rosa Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
4 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Monte Rosa Therapeutics is held by insiders.
Percentage Held by Institutions
79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($2.25) to ($2.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Monte Rosa Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Monte Rosa Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Monte Rosa Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

GLUE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GLUE Stock News Headlines

April 16, 2024 | americanbankingnews.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 8.9%

March 19, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

March 19, 2024 | finance.yahoo.com

Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know

March 16, 2024 | finance.yahoo.com

Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results

March 15, 2024 | finance.yahoo.com

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

March 14, 2024 | markets.businessinsider.com

Promising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa Therapeutics

March 14, 2024 | investorplace.com

GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

March 14, 2024 | finanznachrichten.de

Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 14, 2024 | benzinga.com

Monte Rosa Therapeutics: Q4 Earnings Insights

March 14, 2024 | globenewswire.com

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 11, 2024 | globenewswire.com

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

March 1, 2024 | morningstar.com

Monte Rosa Therapeutics Inc GLUE

February 24, 2024 | msn.com

Monte Rosa Therapeutics (GLUE) Price Target Increased by 5.66% to 16.32

February 23, 2024 | benzinga.com

Monte Rosa Therapeutics Stock (NASDAQ:GLUE), Analyst Ratings, Price Targets, Predictions

February 15, 2024 | msn.com

Monte Rosa draws bullish view at Wedbush on protein degradation

February 15, 2024 | msn.com

Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst

January 16, 2024 | fool.com

3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street

January 8, 2024 | finance.yahoo.com

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

January 3, 2024 | finance.yahoo.com

Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 4, 2023 | benzinga.com

Monte Rosa Therapeutics Stock (NASDAQ:GLUE) Earnings Dates and Earning Calls

December 4, 2023 | benzinga.com

Monte Rosa Therapeutics Stock (NASDAQ:GLUE) Dividends: History, Yield and Dates

November 21, 2023 | finance.yahoo.com

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

November 14, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)

November 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)

November 9, 2023 | benzinga.com

Monte Rosa Therapeutics: Q3 Earnings Insights

See More Headlines

Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:GLUE
CUSIP: N/A
CIK: 1826457
Web: www.monterosatx.com
Phone: 617-949-2643
Fax: N/A
Employees: 133
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +89.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-135,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -65.93%
Return on Assets: -47.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.07
Quick Ratio: 5.07

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.58 per share
Price / Book: 1.63

Miscellaneous

Outstanding Shares: 50,150,000
Free Float: 47,492,000
Market Cap: $291.87 million
Optionable: Optionable
Beta: 1.45

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Markus Warmuth M.D. (Age 52)
President, CEO & Director
Comp: $901.35k
Dr. Owen B. Wallace Ph.D. (Age 55)
Chief Scientific Officer
Comp: $630.68k
Dr. Filip Janku M.D. (Age 49)
Ph.D., Chief Medical Officer
Comp: $658.66k
Ms. Jennifer Champoux
Chief People & Operations Officer
Dr. Sharon Townson Ph.D. (Age 49)
Chief Technology Officer
Dr. John C. Castle Ph.D. (Age 52)
Chief Data & Information Officer
Mr. Andrew Funderburk
Senior VP and Head of IR & Strategic Finance
Mr. Philip Nickson J.D. (Age 45)
Ph.D., General Counsel
Mr. Magnus Walter DPHIL
Senior Vice President of Drug Discovery
Mr. Edmund Dunn (Age 58)
Vice President & Corporate Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GLUE Stock Analysis - Frequently Asked Questions

Should I buy or sell Monte Rosa Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GLUE shares.
View GLUE analyst ratings or view top-rated stocks.
What is Monte Rosa Therapeutics' stock price target for 2024?: 3 brokers have issued 1-year price objectives for Monte Rosa Therapeutics' stock. Their GLUE share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 85.8% from the stock's current price.
View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts.
How have GLUE shares performed in 2024?: Monte Rosa Therapeutics' stock was trading at $5.65 on January 1st, 2024. Since then, GLUE stock has increased by 4.8% and is now trading at $5.92.
View the best growth stocks for 2024 here.
Are investors shorting Monte Rosa Therapeutics?: Monte Rosa Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 1,680,000 shares, a drop of 8.2% from the March 15th total of 1,830,000 shares. Based on an average daily volume of 150,300 shares, the short-interest ratio is currently 11.2 days. Approximately 5.3% of the company's shares are sold short.
View Monte Rosa Therapeutics' Short Interest.
When is Monte Rosa Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GLUE earnings forecast.

How were Monte Rosa Therapeutics' earnings last quarter?: Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its earnings results on Thursday, March, 14th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.01.
What ETF holds Monte Rosa Therapeutics' stock?: Range Cancer Therapeutics ETF holds 18,664 shares of GLUE stock, representing 1.26% of its portfolio.
When did Monte Rosa Therapeutics IPO?: Monte Rosa Therapeutics (GLUE) raised $211 million in an IPO on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.
How do I buy shares of Monte Rosa Therapeutics?: Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLUE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial